The company has a discovery platform that identifies the most effective combinations of chemicals to improve the safety and therapeutic profiles of existing psychedelic therapeutics. They have a diverse portfolio of assets, including programs with clinical data and multiple exploratory programs, that aim to revolutionize the treatment of mental health indications. Co-founded by Dr. John Krystal, Chair of the Department of Psychiatry at Yale University, and Dina Burkitbayeva, co-founder of PsyMed Ventures, Freedom Biosciences is poised to make a significant impact in the biotech industry.